Sarepta secures rights to develop and market in EU, CIS and Turkey to Summit's utrophin modulator pipeline, including ezutromid for DMD.
Sarepta Therapeutics and Summit Therapeutics plc announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States ("the licensed territory"), to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy (DMD). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit's utrophin modulator pipeline. Summit retains commercialization rights in all other countries.
Sarepta has recently secured FDA approval for its Exondys 51 (eteplirsen) to treat Duchenne Muscular Dystrophy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins